Member list of California Life Sciences Association

Below you find a list of all members of CLSA in alphabetical order.

Results 341 - 360 out of 950 displayed.
 
Sort direction:
Sort direction:
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 »
Entrotech life sciences, inc.   
San Francisco, USA
Entrotech Life Sciences, Inc. (ELS) specializes in developing advanced antimicrobial film technologies to prevent infections in healthcare settings. Their core product line, including PrevahexCHX and ChloraDerm, provides transparent film dressings that secure IV catheters and protect wounds around percutaneous medical devices.
Envivo Bio Inc.   
San Francisco, USA
Envivo Bio is a biotech company advancing the gut microbiome and metabolome field. The company has developed CapScan, an investigational ingestible device designed to sample and analyze the gut regionally.
enVVeno Medical   
Irvine, USA
enVVeno Medical Corp is a late clinical-stage medical device company developing innovative solutions for venous disease treatment. The company's lead product, VenoValve, is a surgical replacement venous valve in a U.S. pivotal study, while its second product, enVVe, is a non-surgical, transcatheter-based replacement venous valve. Both products aim to improve blood flow in the legs by acting as one-way valves to assist in propelling blood back to the heart and lungs.
Epalex Corporation   
Mountain View, USA
Epalex is a clinical-stage pharmaceutical company developing therapies for migraine and epilepsy. The company's drug candidates provide effective relief. The company is developing EP102 for the acute treatment of migraine headache pain and related symptoms and EP103 for the control of seizure disorders such as epilepsy.
EpicentRx Inc.   
La Jolla, USA
EpicentRx is a clinical-stage biopharmaceutical company with a complementary pipeline of small molecules, novel drug delivery devices, and cancer selective virus platforms that target inflammatory diseases of significant unmet need. The company's product AdAPT-001 is designed to express a potent TGFβR inhibitor for local TGFβ neutralization, decreased Treg cell function, and superior therapeutic responses in combination with checkpoint inhibitors for several tumor types including STS, colorectal...
Epicrispr Biotechnologies   
South San Francisco, USA
Epic Bio is an epigenetic editing company that modifies gene expression without cutting DNA sequences. The company's product EPI-321 is an investigational epigenetic therapy that aims to address the underlying molecular mechanisms of FSHD with a one-time dose. The company's another product EPI-331 is an experimental, in vivo epigenetic therapy for Duchenne muscular dystrophy (DMD).
Epigen Biosciences, Inc.   
San Diego, USA
Epigen Biosciences is a pharmaceutical company that is discovering proprietary drugs to address unmet medical needs. The company employs advanced hit-to-lead and lead optimization techniques. These encompass computational design, scaffold-hopping, focused library synthesis, and screening. Epigen harness cutting-edge in silico drug discovery tools, intricately coupled with meticulous property assessment for Absorption, Distribution, Metabolism, and Excretion (ADME). These methodologies and processes...
Epigenome Technologies   
San Diego, USA
Epigenome Technologies, Inc. is focused on developing advanced tools and analytical platforms to study epigenetic regulation at single-cell resolution. The company applies multi-omics technologies to measure epigenetic marks such as DNA methylation, chromatin accessibility, and gene-expression changes across individual cells, enabling a deeper understanding of disease biology. Epigenome Technologies platforms are designed to support academic, pharmaceutical, and clinical researchers working...
Eppendorf North America   
Enfield, USA
Eppendorf, North America is a Eppendorf AG (Hamburg, Germany) subsidiary. Eppendorf, North America provides total customer support and service: taking/tracking orders; product installation and training; application support; calibration services; general product maintenance and repair,etc.
Erasca, Inc.   
San Diego, USA
Erasca, Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors.
Escient Pharmaceuticals   
San Diego, USA
Escient Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory diseases. The company's pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell-mediated disorders and MRGPRX4 for cholestatic pruritus.
Esvyda! Inc   
Campbell, USA
Esvyda is a virtual care solution HIPAA compliant for healthcare providers that allows secure communication, video, remote patient monitoring of vital signs such as blood pressure, weight, glucose, oxygen and temperature and physical activity using wearables. providing relevant data to clinicians, care teams and caregivers. The firm is now offering an exam room app, which helps to provide error-free information of vital signs directly uploaded to medical records of patients previous face-to-face...
Eternal Technology Corporation   
Colonial Heights, USA
Eternal Technology CORP's line of business includes the wholesale distribution of miscellaneous industrial supplies. The company focuses on the production of PCB boards. Some of the products are NIT200 Series, LDF515F, UD900 Series etc.
Ethos Commercial Advisors LLC   
Portland, USA
Ethos Commercial Advisors is a boutique commercial brokerage firm based in Portland, Oregon serving the Pacific Northwest. The company provides market insights, creative solutions and personalized real estate brokerage services.
Eurofins Beacon Discovery, Inc.   
San Diego, USA
Eurofins Beacon Discovery is a drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research. The company provides integrated drug discovery services, including assay development, high-throughput screening (HTS), medicinal chemistry, and computational chemistry.
EvaluatePharma USA, Inc.,   
Boston, USA
EvaluatePharma offers consensus forecasts, global market intelligence, financial data & valuation tools for pharma and biotech.
Evommune, Inc.   
Palo Alto, USA
Evommune, Inc. is a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases. The company's product MRGPRX2 is a G-Protein-Coupled-Receptor (GPCR) found on mast cells (MC) and sensory neurons. It facilitates potent degranulation in MCs, and on sensory neurons, driving neurogenic inflammation and sensations such as cough, pain, and itch.
Evotec (US), Inc   
Princeton, USA
Evotec is a drug discovery alliance and development partnership company focused on pharmaceutical and biotechnology companies. The company operates in preclinical research and development, including molecular biology, medicinal chemistry, in vitro and in vivo pharmacology, drug metabolism, pharmacokinetics, toxicology, and informatics.
ExcepGen   
San Francisco, USA
ExcepGen, Inc. is a privately held biotechnology company focused on developing technologies for RNA medicines, vaccines, gene therapies, and other biotherapeutics. Its key technology is the RNAx platform, an mRNA-encoded protein designed to modify the cellular response to RNA and lipid nanoparticles (LNPs) by dampening excessive innate immune activation. The company is currently focused on self-amplifying mRNA vaccines, trans-amplifying mRNA vaccines, and conventional mRNA vaccines.
Exelixis, Inc.   
Alameda, USA
Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company has developed four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib), and MINNEBRO® (esaxerenone). CABOMETYX is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy. COMETRIQ is a kinase...

«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 »

Disclaimer: Any membership totals displayed reflect organizations who have agreed to display their membership information and may not be indicative of CLSA's total member population.

© Biotechgate by Venture Valuation